EMA Authorised: Lojuxta (Lomitapide) — Chiesi Farmaceutici SpA

View source ↗

Summary

LOJUJTA (lomitapide) has been authorised in the EU for hypercholesterolemia by Chiesi Farmaceutici, marking an approval decision.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• LOJUJTA (lomitapide)

Snippet

Status: Authorised. Therapeutic area: Hypercholesterolemia. MAH: Chiesi Farmaceutici SpA. Decision date: 03/06/2026